Startups

Emergent Biosolutions doubles size of vaccine manufacturing operation in Bayview

The facility has produced Ebola and Zika treatments during recent outbreaks.

Emergent Biosolutions' Bayview facility. (Courtesy photo)

The U.S. Health and Human Services Department designates three centers to develop and manufacture vaccines that can respond to public health threats.
One of them is in Baltimore, and it just doubled in size.
The Emergent Biosolutions facility, which is in Bayview, is now 112,000 square feet.
Equipped with lab, manufacturing and offices, it’s designed so that Emergent can produce vaccines and treatments quickly when ordered.
Since the partnership to make the site a Center for Innovation in Advanced Development and Manufacturing was inked in 2012, the facility has already completed orders to develop therapeutics during the Ebola crisis, as well as a Zika vaccine candidate.


Emergent, which is based in Gaithersburg, is known in biopharmaceutical circles for developing the only anthrax vaccine that was approved by the FDA. The company also uses the Baltimore facility to manufacture its own candidate products.
The company is another sign of the effort to knit Maryland’s biotech community between Baltimore and I-270 more closely together. Advances in vaccines are being developed in the city at University of Maryland-Baltimore and Johns Hopkins University, and the companies that spin out from the research that goes on at those institutions. The facility’s expansion shows the products can be made here, as well.
Along with providing medical needs, Emergent will also create jobs in Baltimore. That was a focus of remarks by officials at a ribbon-cutting on Wednesday.
“They are at the forefront of innovation, and represent everything we want in a Baltimore-area company,” said City Council President Bernard C. “Jack” Young, according to prepared remarks. “Emergent also continues to emphasize local hiring, which I have fought hard to promote so we can increase job opportunities and put our city to work.”

Companies: Emergent BioSolutions

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

3 ways to support our work:
  • Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
  • Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
  • Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
The journalism fund Preferred partners Our services
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

A new model for thinking about how to grow regional economies: the Innovation Ecosystem Stack

Can the nation’s biggest cyber hub even handle Craiglist founder’s $100M security pledge?

20 tech community events in October you won’t want to miss

Johns Hopkins’ Pava Center picks promising startups in AI, healthcare and music 

Technically Media